Jeffrey A. Engelman
Selecta Biosciences (United States)(US)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Melanoma and MAPK Pathways, Colorectal Cancer Treatments and Studies, Cancer Genomics and Diagnostics, Lung Cancer Research Studies
Most-Cited Works
- → Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer(2010)4,491 cited
- → MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling(2007)4,440 cited
- → Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors(2011)3,534 cited
- → The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism(2006)3,288 cited
- → Systematic identification of genomic markers of drug sensitivity in cancer cells(2012)2,534 cited
- → Targeting PI3K signalling in cancer: opportunities, challenges and limitations(2009)2,438 cited
- → Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway(2017)1,941 cited
- → ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers(2012)1,547 cited
- → Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints(2016)1,544 cited
- → Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer(2014)1,469 cited